Approaches to the Treatment of Diabetic Retinopathy
Keywords:
Neovascular diseases, growth factor, intravitreal injections, diabetic retinopathy, PRP.Abstract
x
Downloads
References
Das A. Diabetic Retinopathy: Battling the Global Epidemic. Investig. Ophthalmol. Vis. Sci. 2016;57:6669–6682. doi: 10.1167/iovs.16-21031.
Spencer B.G., Estevez J.J., Liu E., Craig J.E., Finnie J.W. Pericytes, inflammation, and diabetic retinopathy. Inflammopharmacology. 2020;28:697–709. doi: 10.1007/s10787-019-00647-9.
Romero-Aroca P., Baget-Bernaldiz M., Pareja-Rios A., Lopez-Galvez M., Navarro-Gil R., Verges R. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J. Diabetes Res. 2016;2016:2156273. doi: 10.1155/2016/2156273.
Roy S., Kim D. Retinal capillary basement membrane thickening: Role in the pathogenesis of diabetic retinopathy. Prog. Retin. Eye Res. 2020;82:100903. doi: 10.1016/j.preteyeres.2020.100903.
Amoaku W.M., Ghanchi F., Bailey C., Banerjee S., Banerjee S., Downey L., Gale R., Hamilton R., Khunti K., Posner E., et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye. 2020;34:1–51. doi: 10.1038/s41433-020-0961-6.
Semeraro F., Morescalchi F., Cancarini A., Russo A., Rezzola S., Costagliola C. Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications. Diabetes Metab. 2019;45:517–527. doi: 10.1016/j.diabet.2019.04.002.
Behl T., Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol. Res. 2015;99:137–148. doi: 10.1016/j.phrs.2015.05.013.
Rodrigues E.B., Farah M.E., Maia M., Penha F.M., Regatieri C., Melo G.B., Pinheiro M.M., Zanetti C.R. Therapeutic monoclonal antibodies in ophthalmology. Prog. Retin. Eye Res. 2009;28:117–144. doi: 10.1016/j.preteyeres.2008.11.005.
Filho J.A., Messias A., Almeida F.P., Ribeiro J.A., Costa R.A., Scott I.U., Jorge R. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol. 2011;89:e567–e572. doi: 10.1111/j.1755-3768.2011.02184.x.
Figueira J., Fletcher E., Massin P., Silva R., Bandello F., Midena E., Varano M., Sivaprasad S., Eleftheriadis H., Menon G., et al. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study) Ophthalmology. 2018;125:691–700. doi: 10.1016/j.ophtha.2017.12.008.
Lang G.E., Stahl A., Voegeler J., Quiering C., Lorenz K., Spital G., Liakopoulos S. Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy-the PRIDE study. Acta Ophthalmol. 2019 doi: 10.1111/aos.14312.
Chatziralli I., Dimitriou E., Theodossiadis G., Kazantzis D., Theodossiadis P. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: Long-term outcomes of a prospective study. Acta Diabetol. 2020;57:1219–1225. doi: 10.1007/s00592-020-01548-y.
Ferraz D.A., Vasquez L.M., Preti R.C., Motta A., Sophie R., Bittencourt M.G., Sepah Y.J., Monteiro M.L., Nguyen Q.D., Takahashi W.Y. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy. Retina. 2015;35:280–287. doi: 10.1097/IAE.0000000000000363.
Cao G., Xu X., Wang C., Zhang S. Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation. Eur. J. Ophthalmol. 2020;30:34–39. doi: 10.1177/1120672118812270.
. Comyn O., Wickham L., Charteris D.G., Sullivan P.M., Ezra E., Gregor Z., Aylward G.W., da Cruz L., Fabinyi D., Peto T., et al. Ranibizumab pretreatment in diabetic vitrectomy: A pilot randomised controlled trial (the RaDiVit study) Eye. 2017;31:1253–1258. doi: 10.1038/eye.2017.75.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in the Journal of Applied Science and Social Science (JASSS) is protected by copyright. Authors retain the copyright to their work, and grant JASSS the right to publish the work under a Creative Commons Attribution License (CC BY). This license allows others to distribute, remix, adapt, and build upon the work, even commercially, as long as they credit the author(s) for the original creation.
